Terrific posts truss. With such a deadly disease, approval will come quickly if results are good. Approval for aGvHD would result in a MC well in excess of $1B. That's about 20 x the current SP. Still a few risks of course but there is a tremendous upside if data is good.
Why Cynata's GvHD Treatment Might Not Need a Phase Two Trial for FDA Approval, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 277684 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 54843 | 3 |
View Market Depth
| Last trade - 10.48am 17/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable